Using cost-effectiveness for subsidy decisions.
Glasziou
P
P
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000191:economics / Q000628:therapy*; D003362:Cost-Benefit Analysis; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab